Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatm...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karolinum Press
2003-01-01
|
| Series: | Acta Medica |
| Subjects: | |
| Online Access: | https://actamedica.lfhk.cuni.cz/46/4/0215/ |
| _version_ | 1811274166320496640 |
|---|---|
| author | Norihiro Kikuchi Hiroaki Satoh Takahide Kodama Norihiro Haraguchi Kiyohisa Sekizawa |
| author_facet | Norihiro Kikuchi Hiroaki Satoh Takahide Kodama Norihiro Haraguchi Kiyohisa Sekizawa |
| author_sort | Norihiro Kikuchi |
| collection | DOAJ |
| description | We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy. |
| first_indexed | 2024-04-12T23:12:49Z |
| format | Article |
| id | doaj.art-8fa645be71ac44a2863a9f02a691c43e |
| institution | Directory Open Access Journal |
| issn | 1211-4286 1805-9694 |
| language | English |
| last_indexed | 2024-04-12T23:12:49Z |
| publishDate | 2003-01-01 |
| publisher | Karolinum Press |
| record_format | Article |
| series | Acta Medica |
| spelling | doaj.art-8fa645be71ac44a2863a9f02a691c43e2022-12-22T03:12:45ZengKarolinum PressActa Medica1211-42861805-96942003-01-0146421521610.14712/18059694.2019.37Response to Gefitinib in Pericardial Effusion Due to Lung CancerNorihiro Kikuchi0Hiroaki Satoh1Takahide Kodama2Norihiro Haraguchi3Kiyohisa Sekizawa4University of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, JapanUniversity of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, JapanUniversity of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, JapanUniversity of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, JapanUniversity of Tsukuba, Institute of Clinical Medicine, Division of Respiratory Medicine, JapanWe described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.https://actamedica.lfhk.cuni.cz/46/4/0215/Lung cancerGefitinibPericardial effusion |
| spellingShingle | Norihiro Kikuchi Hiroaki Satoh Takahide Kodama Norihiro Haraguchi Kiyohisa Sekizawa Response to Gefitinib in Pericardial Effusion Due to Lung Cancer Acta Medica Lung cancer Gefitinib Pericardial effusion |
| title | Response to Gefitinib in Pericardial Effusion Due to Lung Cancer |
| title_full | Response to Gefitinib in Pericardial Effusion Due to Lung Cancer |
| title_fullStr | Response to Gefitinib in Pericardial Effusion Due to Lung Cancer |
| title_full_unstemmed | Response to Gefitinib in Pericardial Effusion Due to Lung Cancer |
| title_short | Response to Gefitinib in Pericardial Effusion Due to Lung Cancer |
| title_sort | response to gefitinib in pericardial effusion due to lung cancer |
| topic | Lung cancer Gefitinib Pericardial effusion |
| url | https://actamedica.lfhk.cuni.cz/46/4/0215/ |
| work_keys_str_mv | AT norihirokikuchi responsetogefitinibinpericardialeffusionduetolungcancer AT hiroakisatoh responsetogefitinibinpericardialeffusionduetolungcancer AT takahidekodama responsetogefitinibinpericardialeffusionduetolungcancer AT norihiroharaguchi responsetogefitinibinpericardialeffusionduetolungcancer AT kiyohisasekizawa responsetogefitinibinpericardialeffusionduetolungcancer |